PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.43%
Net income growth under 50% of AXSM's 43.58%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.55%
Negative yoy SBC while AXSM is 94.42%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
69.28%
Slight usage while AXSM is negative at -1777.77%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
A yoy AP increase while AXSM is negative at -326.57%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-92.45%
Both reduce yoy usage, with AXSM at -37.30%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
109.32%
Some yoy increase while AXSM is negative at -97.56%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.94%
Operating cash flow growth 1.25-1.5x AXSM's 18.81%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.52%
We cut debt repayment yoy while AXSM is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1850.82%
Issuance growth of 1850.82% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.